Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 19/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.83 |
| ▸ | ALPL | P05186 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23258335 | 0.96 | PPARG (0.77) | PPARGCYP3A4ALPL | |
| SCHEMBL22732150 | 0.92 | PPARG (0.79) | PPARGCYP3A4ALPL | |
| Int131 SCHEMBL29404335 | 0.91 | PPARG (1.00) | PPARGCYP3A4 | |
| Int131 SCHEMBL30035369 | 0.91 | PPARG (1.00) | PPARGCYP3A4 | |
| Int131 SCHEMBL634767 | 0.91 | PPARG (1.00) | PPARGCYP3A4 | |
| SCHEMBL24268600 | 0.90 | PPARG (0.87) | PPARGCYP3A4 | |
| Int131 SCHEMBL635008 | 0.90 | PPARG (0.98) | PPARGCYP3A4 | |
| SCHEMBL23258024 | 0.89 | PPARG (0.73) | PPARGCYP3A4ALPL | |
| SCHEMBL23258936 | 0.89 | PPARG (0.80) | PPARGCYP3A4ALPL | |
| SCHEMBL22203939 | 0.88 | PPARG (0.83) | PPARGCYP3A4ALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021076616-A1 | COMPOSITIONS AND METHODS TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASES (NAFLD) | Coherus Biosciences, Inc. (US) | 2021-04-22 | — | — | WO | disclosed |
| WO-2020243058-A1 | COMPOSITIONS AND METHODS TO TREAT CANCER | Coherus Biosciences, Inc. (US) | 2020-12-03 | — | — | WO | disclosed |
| WO-2009111078-A2 | COMBINATION OF A PPARY AGONIST AND A DIPEPTIDYL PEPTIDASE-INHIBITOR FOR THE TREATMENT OF DIABETES AND OBESITY | INTEKRIN THERAPEUTICS, INC. (US) | 2009-09-11 | — | — | WO | disclosed |